ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

109
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Refresh
05 Aug 2024 00:32

Merger Arb Mondays (05 Aug) - Henlius, Asia Cement, Canvest, GA Pack, CPMC, A8, Fancl

This week, the highest gross spreads are HEC Pharma (123.7%), China TCM (36.1%), Asia Cement China (11.4%), Canvest (11.4%), Henlius (8.8%),...

Logo
282 Views
Share
12 Jul 2024 09:36

Henlius (2696 HK): Here Comes The Scrip Option

This is trading wide-ish at 8.8%/28.8% currently (assuming mid-Nov payment), ostensibly due to the timing on the regulatory approvals - TCM (570...

Logo
386 Views
Share
12 Jul 2024 08:50

Shanghai Henlius Biotech Update (2696.HK) - The Story Behind Privatization

Henlius has met the pre-condition for a potential Share Alternative Offer. Since HK$24.60 Offer Price (50% lower than HK$49.6/share IPO price) is...

Logo
627 Views
Share
11 Jul 2024 22:06

Henlius (2696 HK): Dilemma as the Scrip Pre-Condition Met and a Substantial Shareholder Emerges

The likely scenario is that the offer succeeds as the co-founders enter rollover arrangements, and a share alternative is introduced, which is...

Logo
356 Views
Share
01 Jul 2024 00:27

Merger Arb Mondays (01 Jul) - Henlius, China TCM, GA Pack, CPMC, Asia Cement, Great Eastern

This week, the highest gross spreads are HEC Pharma (121.3%), China TCM (26.7%), Hollysys (22.5%), Ansarada (13.1%), Asia Cement China (12.6%), A8...

Logo
400 Views
Share
x